全球液態生物檢體市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

全球液態生物檢體市場預計將從2025年的67.8億美元成長至2034年的192.3億美元，2026年至2034年的複合年成長率（CAGR）為12.28%。隨著醫療專業人員擴大採用微創診斷技術進行癌症檢測和疾病監測，該市場正經歷快速成長。液態生物檢體能夠透過血液樣本分析循環腫瘤DNA、循環性腫瘤細胞和其他生物標記物，為傳統的組織切片檢查提供了更快、更微創的替代方案。癌症發生率的上升、對精準醫療需求的不斷成長以及分子診斷技術的持續進步，正在推動液體活體組織切片在醫療保健系統中的廣泛應用。腫瘤學研究的拓展和個人化治療策略的進步也進一步促進了市場的發展。

次世代定序、聚合酵素鏈鎖反應(PCR) 和生物標記分析等技術的創新正在提高液態生物檢體的準確性和可靠性。製藥公司和研究機構正在利用這些技術來支援藥物研發、治療監測和疾病早期檢測。臨床研發投入的增加、有利的監管支持以及應用範圍在腫瘤學以外的拓展，都創造了巨大的成長機會。與人工智慧 (AI) 和生物資訊學平台的整合進一步提高了診斷效率。

鑑於精準醫療和疾病早期檢測在全球範圍內日益受到重視，前景十分光明。基因組學、自動化和多癌種篩檢解決方案的進步將拓展臨床應用，並改善患者預後。醫療領域投資的增加、對非侵入性診斷認知的不斷提高以及生物標記研究的持續創新將推動市場長期成長。液態生物檢體有望成為個人化醫療和疾病管理的重要組成部分。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、阻礙因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為指定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別預期的未來趨勢。

區域分析：我們全面檢驗主要地理區域的市場表現，識別高成長領域和區域趨勢，並深入了解每個區域特有的市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，從而更有效地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球液態生物檢體市場：依產品分類

• 市場分析、洞察與預測
• 耗材（試劑盒和試劑、檢測方法和檢測板）
• 裝置
• 服務

第5章：全球液態生物檢體市場：依生物標記分類

• 市場分析、洞察與預測
• 循環性腫瘤細胞（CTCs）
• 循環腫瘤DNA（ctDNA）
• 無細胞DNA（cfDNA）
• 細胞外囊泡
• 其他生物標記

第6章：全球液態生物檢體市場：依疾病適應症分類

• 市場分析、洞察與預測
• 癌症（肺癌、乳癌、大腸癌、攝護腺癌及其他癌症）
• 非癌症（無創產前檢查、器官移植、傳染病檢查）

第7章 全球液態生物檢體市場：依臨床應用分類

• 市場分析、洞察與預測
• 監測治療進展
• 預後和復發監測
• 治療方案
• 診斷和篩檢

第8章：全球液態生物檢體市場：依技術分類

• 市場分析、洞察與預測
• 下一代擴展（NGS）
• 單基因分析（PCR、微陣列）

第9章 全球液態生物檢體市場：依最終用戶分類

• 市場分析、洞察與預測
• 醫院
• 研究實驗室
• 臨床實驗室
• 其他最終用戶

第10章 全球液態生物檢體市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第11章 競爭格局

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第12章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • ANGLE Plc
  • Biocept
  • Bio-Rad Laboratories
  • Epigenomics AG
  • F. Hoffmann-La Roche
  • Freenome Holdings
  • GRAIL
  • Guardant Health
  • Illumina
  • Lucence Health
  • MDxHealth
  • Menarini Group
  • Myriad Genetics
  • Natera
  • QIAGEN
  • Sysmex Corporation
  • Thermo Fisher Scientific

The global liquid biopsy market size is expected to reach USD 19.23 Billion in 2034 from USD 6.78 Billion in 2025, growing at a CAGR of 12.28 during 2026-2034.This market is experiencing rapid growth as healthcare providers increasingly adopt minimally invasive diagnostic technologies for cancer detection and disease monitoring. Liquid biopsy enables the analysis of circulating tumor DNA, circulating tumor cells, and other biomarkers through blood samples, offering a faster and less invasive alternative to traditional tissue biopsies. Rising cancer prevalence, growing demand for precision medicine, and continuous advancements in molecular diagnostics are driving widespread adoption across healthcare systems. Expanding research in oncology and personalized treatment strategies is further supporting market development.

Technological innovations in next-generation sequencing, polymerase chain reaction, and biomarker analysis are improving the accuracy and reliability of liquid biopsy testing. Pharmaceutical companies and research institutions are utilizing these technologies to support drug development, treatment monitoring, and early disease detection. Increasing investments in clinical research, favorable regulatory support, and expanding applications beyond oncology are creating significant growth opportunities. Integration with artificial intelligence and bioinformatics platforms is further enhancing diagnostic efficiency.

The future outlook remains highly promising as precision healthcare and early disease detection continue gaining importance worldwide. Advances in genomic technologies, automation, and multi-cancer screening solutions will expand clinical applications and improve patient outcomes. Increasing healthcare investments, rising awareness of non-invasive diagnostics, and continuous innovation in biomarker research will strengthen long-term market growth. Liquid biopsy is expected to become an integral component of personalized healthcare and disease management.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Product

• Consumables (Kits and Reagents, Assays and Panels)
• Instruments
• Services

By Biomarkers

• Circulating Tumor Cells (CTCs)
• Circulating Tumor DNA (ctDNA)
• Cell-Free DNA (cfDNA)
• Extracellular Vesicles
• Other Biomarkers

By Disease Indication

• Cancer (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Other Cancers)
• Non-Cancer (Non-Invasive Prenatal Testing, Organ Transplantation, Infectious Disease Testing)

By Clinical Application

• Treatment Monitoring
• Prognosis and Recurrence Monitoring
• Treatment Selection
• Diagnosis and Screening

By Technology

• Multi-Gene Parallel Analysis (NGS)
• Single-Gene Analysis (PCR, Microarrays)

By End User

• Hospitals
• Research Laboratories
• Clinical Laboratories
• Other End Users

COMPANIES PROFILED

• ANGLE plc, Biocept, Bio-Rad Laboratories, Epigenomics AG, F. Hoffmann-La Roche, Freenome Holdings, GRAIL, Guardant Health, Illumina, Lucence Health, MDxHealth, Menarini group, Myriad Genetics, Natera, QIAGEN, Sysmex Corporation, Thermo Fisher Scientific

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL LIQUID BIOPSY MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Consumables (Kits and Reagents, Assays and Panels) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Instruments Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Services Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL LIQUID BIOPSY MARKET: BY BIOMARKERS 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Biomarkers
• 5.2. Circulating Tumor Cells (CTCs) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Circulating Tumor DNA (ctDNA) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Cell-Free DNA (cfDNA) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Extracellular Vesicles Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Other Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL LIQUID BIOPSY MARKET: BY DISEASE INDICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Disease Indication
• 6.2. Cancer (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Other Cancers) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Non-Cancer (Non-Invasive Prenatal Testing, Organ Transplantation, Infectious Disease Testing) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL LIQUID BIOPSY MARKET: BY CLINICAL APPLICATION 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Clinical Application
• 7.2. Treatment Monitoring Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Prognosis and Recurrence Monitoring Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Treatment Selection Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Diagnosis and Screening Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL LIQUID BIOPSY MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Technology
• 8.2. Multi-Gene Parallel Analysis (NGS) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Single-Gene Analysis (PCR, Microarrays) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL LIQUID BIOPSY MARKET: BY END USER 2022-2034 (USD MN)

• 9.1. Market Analysis, Insights and Forecast End User
• 9.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.3. Research Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.4. Clinical Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.5. Other End Users Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 10. GLOBAL LIQUID BIOPSY MARKET: BY REGION 2022-2034 (USD MN)

• 10.1. Regional Outlook
• 10.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.2.1 By Product
  • 10.2.2 By Biomarkers
  • 10.2.3 By Disease Indication
  • 10.2.4 By Clinical Application
  • 10.2.5 By Technology
  • 10.2.6 By End User
  • 10.2.7 United States
  • 10.2.8 Canada
  • 10.2.9 Mexico
• 10.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.3.1 By Product
  • 10.3.2 By Biomarkers
  • 10.3.3 By Disease Indication
  • 10.3.4 By Clinical Application
  • 10.3.5 By Technology
  • 10.3.6 By End User
  • 10.3.7 United Kingdom
  • 10.3.8 France
  • 10.3.9 Germany
  • 10.3.10 Italy
  • 10.3.11 Russia
  • 10.3.12 Rest Of Europe
• 10.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.4.1 By Product
  • 10.4.2 By Biomarkers
  • 10.4.3 By Disease Indication
  • 10.4.4 By Clinical Application
  • 10.4.5 By Technology
  • 10.4.6 By End User
  • 10.4.7 India
  • 10.4.8 Japan
  • 10.4.9 South Korea
  • 10.4.10 Australia
  • 10.4.11 South East Asia
  • 10.4.12 Rest Of Asia Pacific
• 10.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.5.1 By Product
  • 10.5.2 By Biomarkers
  • 10.5.3 By Disease Indication
  • 10.5.4 By Clinical Application
  • 10.5.5 By Technology
  • 10.5.6 By End User
  • 10.5.7 Brazil
  • 10.5.8 Argentina
  • 10.5.9 Peru
  • 10.5.10 Chile
  • 10.5.11 Rest of Latin America
• 10.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.6.1 By Product
  • 10.6.2 By Biomarkers
  • 10.6.3 By Disease Indication
  • 10.6.4 By Clinical Application
  • 10.6.5 By Technology
  • 10.6.6 By End User
  • 10.6.7 Saudi Arabia
  • 10.6.8 UAE
  • 10.6.9 Israel
  • 10.6.10 South Africa
  • 10.6.11 Rest of the Middle East And Africa

Chapter 11. COMPETITIVE LANDSCAPE

• 11.1. Recent Developments
• 11.2. Company Categorization
• 11.3. Supply Chain & Channel Partners (based on availability)
• 11.4. Market Share & Positioning Analysis (based on availability)
• 11.5. Vendor Landscape (based on availability)
• 11.6. Strategy Mapping

Chapter 12. COMPANY PROFILES OF GLOBAL LIQUID BIOPSY INDUSTRY

• 12.1. Top Companies Market Share Analysis
• 12.2. Company Profiles
  • 12.2.1 ANGLE Plc
  • 12.2.2 Biocept
  • 12.2.3 Bio-Rad Laboratories
  • 12.2.4 Epigenomics AG
  • 12.2.5 F. Hoffmann-La Roche
  • 12.2.6 Freenome Holdings
  • 12.2.7 GRAIL
  • 12.2.8 Guardant Health
  • 12.2.9 Illumina
  • 12.2.10 Lucence Health
  • 12.2.11 MDxHealth
  • 12.2.12 Menarini Group
  • 12.2.13 Myriad Genetics
  • 12.2.14 Natera
  • 12.2.15 QIAGEN
  • 12.2.16 Sysmex Corporation
  • 12.2.17 Thermo Fisher Scientific